GC
RCKT icon

Grimes & Company’s Rocket Pharmaceuticals RCKT Stock Holding History

Grimes & Company’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41K Buy
12,001
+454
+4% +$1.51K ﹤0.01% 447
2026
Q1 		$41.3K Sell
11,547
-1,098
-9% -$4.36K ﹤0.01% 432
2025
Q4 		$44.4K Sell
12,645
-2,766
-18% -$9.47K ﹤0.01% 458
2025
Q3 		$50.2K Buy
+15,411
New +$48.5K ﹤0.01% 449

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Grimes & Company's RCKT Position: Q2 2026 in Review

Grimes & Company increased its Rocket Pharmaceuticals (RCKT) stake by 3.9% in Q2 2026, buying an estimated $1.51K and bringing the position to 12,001 shares worth $41K. The position accounts for ﹤0.01% of the portfolio, ranked #447.

Grimes & Company first reported a position in RCKT in Q3 2025 and has held it in 4 quarters since. The position peaked at $50.2K in Q3 2025. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • Grimes & Company held 12,001 shares of Rocket Pharmaceuticals worth $41K as of Q2 2026.
  • Grimes & Company bought 454 Rocket Pharmaceuticals shares in Q2 2026, an estimated $1.51K.
  • Rocket Pharmaceuticals made up ﹤0.01% of Grimes & Company's portfolio in Q2 2026, its #447 holding.
  • Grimes & Company first reported a position in Rocket Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Grimes & Company's Rocket Pharmaceuticals position peaked at $50.2K in Q3 2025.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Grimes & Company's 13F filing for Q2 2026, filed 17 Jul 2026.